Condition: Acute Myeloid Leukemia · Sponsor: Centre Hospitalier Universitaire de Nice
The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics
This description comes directly from the study's public registry record.
valerie Foussat · +33492034011 · foussat.v@chu-nice.fr
Always discuss trial participation with your own doctor first.
| CHU Amiens Picardie site Sud | Amiens, France | Recruiting |
| CHU d'Angers | Angers, France | Not Yet Recruiting |
| CH Avignon | Avignon, France | Recruiting |
| CHRU Jean Minjoz | Besançon, France | Recruiting |
| Centre Hospitalier de Béziers | Béziers, France | Recruiting |
| Hôpital Avicenne APHP | Bobigny, France | Recruiting |
| Institut d'hématologie de Basse Normandie (IHBN) | Caen, France | Recruiting |
| Hôpital d'Instruction des Armée (HIA) | Clamart, France | Recruiting |
| CHU Estaing | Clermont-Ferrand, France | Recruiting |
| Centre Hospitalier Sud Francilien (CHSF) | Corbeil-Essonnes, France | Recruiting |
| CHU Henri Mondor | Créteil, France | Recruiting |
| Centre Hospitalier de Versailles, Site André Mignot | Le Chesnay, France | Recruiting |
+ 23 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05260528